Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care

April 21, 2020 By The ASCO Post Staff

Hope S. Rugo, MD, of the University of California, San Francisco, discusses an integrated analysis of five clinical trials, in phases I through III, for a variety of advanced cancers. Findings show that patients treated with talazoparib monotherapy had lower hospitalization rates (compared to those receiving chemotherapy) and used less supportive care medication (Abstract CLO20-052).

Related Content